Dr. Reddy's Laboratories Ltd.

DRREDDY

₹6878.65

0.37% (25.45)

Market Cap

₹1,14,982 Cr.

P/E

20.61

About

Dr. Reddy’s Laboratories Limited is a leading India-based pharmaceutical company that started its generics business in India in 1986. Headquartered in Hyderabad, India, the company serves millions of … Read more

Dr. Reddy’s Laboratories Limited is a leading India-based pharmaceutical company that started … Read more

Low

5206

52W Range

High

6966

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

19.74%

3yr Average

16.82%

5yr Average

14.9%

Net Profit Margin

Latest

19.91%

3yr Average

16.1%

5yr Average

14.03%

ROCE

Latest

26.07%

3yr Average

23.11%

5yr Average

19.83%

Debt to Equity

Latest

0.07

3yr Average

0.1

5yr Average

0.12

Market Share

2.04 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

1.39 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

6.51 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

2.62 %

(as of Nov 21)

Historic

Blood Related - Market Share

2.39 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

5.05 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.01 %

(as of Oct 21)

Historic

Endocrinology - Market Share

4.35 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.22 %

(as of Nov 21)

Historic

Gynecology - Market Share

2.63 %

(as of Nov 21)

Historic

Neurological - Market Share

3.84 %

(as of Nov 21)

Historic

Pain - Market Share

3 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

4.38 %

(as of Nov 21)

Historic

Respiratory - Market Share

1.89 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

19.22 %

(as of Nov 21)

Historic

Stomatological - Market Share

7.61 %

(as of Nov 21)

Historic

Urology - Market Share

2.08 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up - Global Generics

Location Wise Break-Up

Therapeutic Area Break-Up - Pharmaceutical Services and Active Ingredients

Therapeutic Area Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Global DMFs filed (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Aarti Industries Ltd.
Elgi Equipments Ltd.
Navin Fluorine International Ltd.
Neuland Laboratories Ltd.
Balaji Amines Ltd.
EPL Ltd.
Borosil Renewables Ltd.
AGI Greenpac Ltd.
TCI Express Ltd.
Shaily Engineering Plastics Ltd.
HLE Glascoat Ltd.
Pennar Industries Ltd.
Control Print Ltd.
Take Solutions Ltd.
Bodhtree Consulting Ltd.

Showing 5 of 15

FAQs on Dr. Reddy's Laboratories Ltd. Business

What does Dr. Reddy's Lab do?

Dr. Reddy’s Laboratories Limited, a leading India-based pharmaceutical company, has been serving millions of patients with high quality and innovative medicines since 1986. It offers a wide range of products and services in the pharmaceutical industry.

Who are the competitors of Dr. Reddy's Lab?

Dr. Reddy's Lab major competitors are Cipla, Zydus Lifesciences, Torrent Pharma, Mankind Pharma, Lupin, Aurobindo Pharma, Alkem Laboratories.
Market Cap of Dr. Reddy's Lab is ₹1,14,982 Crs.
While the median market cap of its peers are ₹83,886 Crs.

Is Dr. Reddy's Lab financially stable compared to its peers?

Dr. Reddy's Lab seems to be less financially stable compared to its peers.
Altman Z score of Dr. Reddy's Lab is 9.97 and is ranked 6 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Jun Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI				Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec